Literature DB >> 11341477

Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat.

J Kuhmonen1, A Haapalinna, J Sivenius.   

Abstract

Increased sympathetic tone is a consequence of cerebral ischemia. Although the role of catecholamines in ischemic damage is still unclear, in some experimental ischemia models alpha2-adrenergic agonism has proved to be neuroprotective. In the present work we have compared the effects of transient and permanent middle cerebral artery occlusion (MCAO) on the infarct volume, and, also, examined whether a selective alpha2-adrenergic receptor agonist, dexmedetomidine (9 microg/kg or 15 microg/kg i.v.), is able to reduce ischemic damage after transient or permanent MCAO in rats. Permanent MCAO led to a significantly larger infarct volume than transient occlusion (p < 0.05). The rats receiving the higher dose of dexmedetomidine were detectected to have smaller (statistically non-significant) infarct volume in the cortex (30.9%) and in the striatum (20.3%) after transient occlusion. Additionally, dexmedetomidine caused significant variations in the physiological parameters.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11341477     DOI: 10.1007/s007020170071

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  14 in total

1.  Effects of chronic and acute oestrogen replacement therapy in aged animals after experimental stroke.

Authors:  F Liu; S E Benashski; Y Xu; M Siegel; L D McCullough
Journal:  J Neuroendocrinol       Date:  2012-02       Impact factor: 3.627

Review 2.  α(2)-adrenoceptors do not mediate neuroprotection in acute ischemic stroke in mice.

Authors:  Marc Brede; Stefan Braeuninger; Friederike Langhauser; Lutz Hein; Norbert Roewer; Guido Stoll; Christoph Kleinschnitz
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-27       Impact factor: 6.200

Review 3.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

4.  Adrenergic receptor antagonism induces neuroprotection and facilitates recovery from acute ischemic stroke.

Authors:  Hiromu Monai; Xiaowen Wang; Kazuko Yahagi; Nanhong Lou; Humberto Mestre; Qiwu Xu; Yoichiro Abe; Masato Yasui; Youichi Iwai; Maiken Nedergaard; Hajime Hirase
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-16       Impact factor: 11.205

5.  ICU sedation with dexmedetomidine after severe traumatic brain injury.

Authors:  Stephen S Humble; Laura D Wilson; Taylor C Leath; Matthew D Marshall; Daniel Z Sun; Pratik P Pandharipande; Mayur B Patel
Journal:  Brain Inj       Date:  2016-07-26       Impact factor: 2.311

6.  Effect of dexmedetomidine on brain edema and neurological outcomes in surgical brain injury in rats.

Authors:  Michael Benggon; Han Chen; Richard Applegate; Robert Martin; John H Zhang
Journal:  Anesth Analg       Date:  2012-05-14       Impact factor: 5.108

7.  Cardiac and renal protective effects of dexmedetomidine in cardiac surgeries: A randomized controlled trial.

Authors:  A S Ammar; K M Mahmoud; Z A Kasemy; M A Helwa
Journal:  Saudi J Anaesth       Date:  2016 Oct-Dec

8.  Dexmedetomidine may benefit cognitive function after laparoscopic cholecystectomy in elderly patients.

Authors:  Jingjun Chen; Junqiang Yan; Xueping Han
Journal:  Exp Ther Med       Date:  2012-11-13       Impact factor: 2.447

Review 9.  Anesthetic challenges for deep brain stimulation: a systematic approach.

Authors:  Rajkalyan Chakrabarti; Mahmood Ghazanwy; Anurag Tewari
Journal:  N Am J Med Sci       Date:  2014-08

10.  The Effect of Dexmedetomidine and Esmolol on Early Postoperative Cognitive Dysfunction After Middle Ear Surgery Under Hypotensive Technique: A Comparative, Randomized, Double-blind Study.

Authors:  Mahmoud Hussein Bahr; Doaa Abu Elkassim Rashwan; Samaa A Kasem
Journal:  Anesth Pain Med       Date:  2020-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.